Fig. 5From: Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinomaCaki-1 (a) and A-498 (b) cells were treated with the SLC6A3 inhibitor sertraline at 12.5 μM, 25 μM and 50 μM; cell proliferation decreased in a dose-dependent mannerBack to article page